The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28557458 |
16 |
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers. |
Novartis Institutes For Biomedical Research |
28279846 |
36 |
Design, synthesis, and biological evaluation of novel 4-anilinoquinazoline derivatives bearing amino acid moiety as potential EGFR kinase inhibitors. |
Xuzhou Medical University |
28109791 |
44 |
Identification of a selective inhibitor of transforming growth factorß-activated kinase 1 by biosensor-based screening of focused libraries. |
Chugai Pharmaceutical |
28088086 |
5 |
Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives. |
University of Sharjah |
27839788 |
60 |
Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells. |
Sichuan University |
27994730 |
6 |
Pyridyl Isonicotinamide Inhibitors of RAF Kinase. |
Dart Neuroscience |
26810260 |
3 |
Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation. |
Hanyang University |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine At Mount Sinai |
26396681 |
58 |
Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. |
Novartis Institutes For Biomedical Research |
26526740 |
111 |
Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors. |
Univ. Lille |
26318056 |
25 |
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. |
Universit£ |
26342867 |
52 |
Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. |
Sichuan University |
26318067 |
34 |
Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors. |
Hanyang University |
25965804 |
80 |
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. |
Eli Lilly |
26071372 |
89 |
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3. |
Astellas Pharma |
25835317 |
63 |
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer. |
Sichuan University |
25086238 |
13 |
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents. |
Shenyang Pharmaceutical University |
24878193 |
8 |
Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors. |
Hanyang University |
25589930 |
62 |
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. |
Lexicon Pharmaceuticals |
25440879 |
13 |
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents. |
Shenyang Pharmaceutical University |
24773549 |
20 |
Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties. |
Development Center For Biotechnology |
24675135 |
4 |
Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents. |
Peking Union Medical College & Chinese Academy of Medical Sciences |
24900832 |
29 |
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning. |
Chugai Pharmaceutical |
23550937 |
72 |
Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties. |
Emory University |
23398453 |
4 |
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors. |
Astrazeneca |
23394126 |
170 |
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). |
Exelixis |
23362959 |
72 |
Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo. |
Sichuan University |
23398373 |
88 |
Design and optimization of selective protein kinase C¿ (PKC¿) inhibitors for the treatment of autoimmune diseases. |
Vertex Pharmaceuticals |
22521646 |
38 |
Novel triazolopyridylbenzamides as potent and selective p38a inhibitors. |
RhôNe-Poulenc Rorer |
22883026 |
34 |
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. |
Takeda Pharmaceutical |
23098265 |
46 |
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. |
University of Genoa |
22808911 |
18 |
Conformation-specific effects of Raf kinase inhibitors. |
Takeda California |
22694093 |
16 |
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. |
National Institute of Biological Sciences |
22548342 |
210 |
Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase¿ inhibitors. |
Exelixis |
22738630 |
76 |
Structure-based optimization of aminopyridines as PKC¿ inhibitors. |
Vertex Pharmaceuticals |
22721924 |
16 |
Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors. |
Academy of Military Medical Sciences |
22452518 |
22 |
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo. |
Sichuan University |
22335519 |
3 |
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties. |
Genentech |
22168626 |
32 |
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. |
Ambit Biosciences |
21353571 |
26 |
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. |
Hanyang University |
18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
17850214 |
99 |
The selectivity of protein kinase inhibitors: a further update. |
University of Dundee |
18578517 |
93 |
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. |
Eberhard Karls University Tuebingen |
18434146 |
28 |
Dual binding site inhibitors of B-RAF kinase. |
Johnson & Johnson Pharmaceutical Research & Development |
18359226 |
50 |
Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. |
Bristol-Myers Squibb Research and Development |
18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
17983756 |
55 |
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. |
Osi Pharmaceuticals |
18346893 |
43 |
Pharmacophore identification of Raf-1 kinase inhibitors. |
China Pharmaceutical University |
16876403 |
85 |
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. |
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories |
15999997 |
85 |
Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. |
Serono Pharmaceutical Research Institute |
15013000 |
31 |
Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. |
Glaxosmithkline |
11591521 |
39 |
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. |
Bayer Research Center |
10698440 |
12 |
The discovery of potent cRaf1 kinase inhibitors. |
Glaxo Wellcome |
22222036 |
9 |
Small molecule inhibitors of BRAF in clinical trials. |
The Institute of Cancer Research |
22014755 |
36 |
Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. |
Hanyang University |
21999461 |
90 |
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase. |
RhôNe-Poulenc Rorer |
21958544 |
31 |
Indolin-2-one p38a inhibitors III: bioisosteric amide replacement. |
RhôNe-Poulenc Rorer |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
21823617 |
58 |
9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. |
Chugai Pharmaceutical |
21813275 |
40 |
Indolin-2-one p38a inhibitors II: Lead optimisation. |
RhôNe-Poulenc Rorer |
21576023 |
2 |
Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors. |
Tsinghua University |
21561771 |
39 |
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors. |
Chugai Pharmaceutical |
21543226 |
26 |
Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. |
Novartis Institutes For Biomedical Research |
20634068 |
2 |
Discovery and optimization of pyrazoline compounds as B-Raf inhibitors. |
Millennium Pharmaceuticals |
21391610 |
139 |
Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. |
Vertex Pharmaceuticals |
21376583 |
232 |
Discovery of triazine-benzimidazoles as selective inhibitors of mTOR. |
Amgen |
21353551 |
23 |
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2. |
Osi Pharmaceuticals |
21420298 |
34 |
Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors. |
Merck Serono |
21341678 |
49 |
Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. |
Millennium Pharmaceuticals |
20961062 |
42 |
Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity. |
Pfizer |
20800479 |
33 |
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. |
Deciphera Pharmaceuticals |
20797858 |
2 |
Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line. |
Institute of Science and Technology |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
19039322 |
50 |
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. |
Center For Molecular Medicine of The Austrian Academy of Sciences |
17108987 |
2 |
New approaches to molecular cancer therapeutics. |
The Institute of Cancer Research |
16783341 |
34 |
Rational design of inhibitors that bind to inactive kinase conformations. |
Novartis Research Foundation |
20466542 |
6 |
1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors. |
Institute of Science and Technology |
20218619 |
44 |
Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. |
Amgen |
20166671 |
85 |
Selectively nonselective kinase inhibition: striking the right balance. |
Schering-Plough |
19864136 |
45 |
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. |
Wyeth Research |
20148563 |
42 |
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring. |
The Institute of Cancer Research |
19888761 |
52 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer. |
Hanmi Research Center |
19356929 |
17 |
Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors. |
Boehringer Ingelheim Pharmaceuticals |
19338355 |
104 |
From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. |
University of Illinois At Chicago |
18947905 |
51 |
Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. |
China Pharmaceutical University |
18818075 |
25 |
The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors. |
Glaxosmithkline |
18691885 |
60 |
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. |
Ariad Pharmaceuticals |
18602262 |
56 |
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. |
Glaxosmithkline |
17848581 |
13 |
Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. |
Wyeth Research |
17560108 |
5 |
New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. |
Boehringer Ingelheim Pharmaceuticals |
16931012 |
61 |
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. |
Targegen |
16890436 |
3 |
Aza-stilbenes as potent and selective c-RAF inhibitors. |
Glaxosmithkline |
16765046 |
63 |
Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. |
Chiron |
15943486 |
8 |
Rapid computational identification of the targets of protein kinase inhibitors. |
University of Iowa |
15454231 |
32 |
A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. |
Astrazeneca |
15177482 |
90 |
Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. |
Novartis Institutes For Biomedical Research |
14741289 |
43 |
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent. |
Bayer Research Center |
12086485 |
10 |
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. |
Boehringer Ingelheim Pharmaceuticals |
11934592 |
24 |
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. |
Merck Research Laboratories |
11597418 |
47 |
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. |
Glaxosmithkline |
11378364 |
34 |
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. |
Research Biomet. Glaxo Wellcome Medicines Research Centre |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors. |
Merck |
27491711 |
422 |
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties. |
Merck And |
30755337 |
95 |
Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952. |
Japan Tobacco |
31789518 |
11 |
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. |
Purdue University |
31284081 |
60 |
Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. |
National Research Centre |
31129450 |
72 |
Estrogen signaling: An emanating therapeutic target for breast cancer treatment. |
Indian Institute of Technology (Bhu) |
31053508 |
34 |
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors. |
China Pharmaceutical University |
10377223 |
57 |
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. |
Merck Research Laboratories |
31693351 |
473 |
Discovery of 4 |
TBA |
30522957 |
35 |
Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors. |
Chung-Ang University |
9873604 |
72 |
Pyrroles and other heterocycles as inhibitors of p38 kinase. |
Merck Research Laboratory |
31077998 |
81 |
Targeting tropomyosin receptor kinase for cancer therapy. |
China Pharmaceutical University |
31059256 |
28 |
Design and Discovery of |
Novartis Institutes For Biomedical Research |
30630714 |
33 |
Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition. |
Hanyang University |
30529543 |
57 |
Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance. |
China Pharmaceutical University |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. |
University of Florida |
31520926 |
28 |
Discovery of a potent p38?/MAPK14 kinase inhibitor: Synthesis, in vitro/in vivo biological evaluation, and docking studies. |
University of Sharjah |
27017549 |
15 |
Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities. |
Korea Institute of Science & Technology (Kist) |
31200237 |
95 |
Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer. |
Shanghai Pharmaceuticals Holding |
24900605 |
43 |
Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties. |
Chugai Pharmaceutical |
30216849 |
18 |
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. |
University of Science & Technology (Ust) |
29940463 |
46 |
Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF |
Nanjing University |
30085668 |
41 |
Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept. |
Institute of Cancer Research |
30082069 |
359 |
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors. |
Vertex Pharmaceuticals |
29945794 |
193 |
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups. |
Vertex Pharmaceuticals |
29547832 |
12 |
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors. |
Universit£ |
29266937 |
36 |
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? |
University of South Australia |
29461827 |
35 |
Current Insights of BRAF Inhibitors in Cancer. |
Albert Einstein College of Medicine |
28927801 |
16 |
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold. |
Jiangxi Science & Technology Normal University |
29886324 |
28 |
Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF |
Southern Medical University |
28242553 |
36 |
Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance. |
China Pharmaceutical University |
16339913 |
6 |
Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. |
University of Tours |
2885412 |
25 |
Alpha-1 adrenergic receptor binding in aortas from rat and dog: comparison of [3H]prazosin and beta-iodo-[125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone. |
Unwersity of Misscuri |
19811924 |
23 |
Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury. |
Dainippon Sumitomo Pharma |
17949010 |
16 |
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. |
Pfizer |
18783203 |
15 |
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. |
Purdue University |
11378361 |
25 |
4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. |
Dupont Pharmaceuticals |